Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

  • Awaiting development
  • GID-TA11087
  • Expected publication date: TBC
This appraisal is now anticipated to begin during early April 2025 when we will write to you about how you can get involved.